David Alleva, PhD, is an immunologist with over two decades of drug discovery and development experience in the biopharma industry.  During this time, he led approximately 20 drug discovery programs among six companies and has successfully brought 10 of these biologic and small-molecule drugs and vaccines to clinical trials for treating/preventing autoimmune and infectious diseases.  Major focus areas are immunotherapeutics for the autoimmune disease, type 1 diabetes (T1D), and vaccines for COVID-19, anthrax, and HIV. 

Dr. Alleva is currently consulting at the Sr. Vice President level with early-stage/start-up biotech companies in autoimmunity and vaccinology via creating, leading, and managing corporate strategies, business plans, and therapeutic development strategies/tactical plans.  In addition, he is very active in funding strategies via networking/pitching to venture capital and pharmaceutical business development organizations in addition to taking full responsibility of non-dilutive financing via grant proposals to NIH, foundations, and clinical funding consortia (e.g., Immune Tolerance Network and TrialNet).  He utilizes his extensive network of first-hand professional relationships with key opinion leaders, researchers, and biopharma industry experts.

Dr. Alleva led the T1D immunotherapeutics investment program and portfolio for the Juvenile Diabetes Research Foundation (JDRF) from 2015 to 2017, which included scientific review, creating/funding biotech start-ups, pharmaceutical partnering, portfolio management, and market analysis.  Prior to his foundation work at JDRF, he led programs in inflammatory, metabolic, angiogenic, infectious and autoimmune diseases at Emergent BioSolutions, Inc., Hollis-Eden Pharmaceuticals, XOMA, Ltd., and Neurocrine Biosciences, Inc. 

Dr. Alleva received a B.S. in biology from Indiana University and a Ph.D. in immunology from the Virginia Polytechnic Institute and State University. He performed postdoctoral research on the genetics of T1D at Boston University Medical Center.